CADTH Health Technology Review - Thrombopoietin Receptor Agonists as Second-Line Treatment in

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] Conclusions will be drawn for each outcome-comparison based on informal appraisals of the certainty of evidence, informed by elements of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.35 The following criteria will be considered: the risk of bias of the contributing studies, the precision of the effect estimates, the consistency of the evidence (in cases whe. [...] (child* or infant* or baby or babies or newborn* or newborns or neonate or neonates or neonatal or preemie? or infancy or paediatric* or pediatric* or toddler* or girl? or boy? or kid? or teen or teens or teenage* or youngster? or youth* or preteen* or adolescent* or adolescence or preschooler* or pre- schooler* or nursery school* or daycare* or school age? or (months adj2 age) or (month? adj2 old. [...] (rituximab* or mabthera* or Rituxan* or GP2013 or GP 2013 or IDEC102 or IDEC 102 or "PF 05280586" or PF05280586 or RG105 or RG 105 or IDEC C2B8 or IDECC2B8 or truxima* or riximyo* or ruxience* or CTP10 or CT P10 or blitzima* or riabni* or ritemvia* or rituenza* or rixathon* or 4F4X42SYQ6).ti,ab,kf,rn,nm,hw,ot. [...] (child* or infant* or baby or babies or newborn* or newborns or neonate or neonates or neonatal or preemie? or infancy or paediatric* or pediatric* or toddler* or girl? or boy? or kid? or teen or teens or teenage* or youngster? or youth* or preteen* or adolescent* or adolescence or preschooler* or pre- schooler* or nursery school* or daycare* or school age? or (months adj2 age) or (month? adj2 old.